The mitochondrial involvement in diabetic cardiomyopathy is currently highlighted since the cardiac benefits of Sodium Glucose Cotransporter 2 inhibitors (SGLT2-i) could be associated with a modulation of mitochondrial function [32]. This evidence concerns the gene SLC5A2 and diabetic cardiomyopathy.